Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 651,853
  • Shares Outstanding, K 189,492
  • Annual Sales, $ 18,140 K
  • Annual Income, $ -72,850 K
  • EBIT $ -83 M
  • EBITDA $ -82 M
  • 60-Month Beta 1.92
  • Price/Sales 36.45
  • Price/Cash Flow N/A
  • Price/Book 6.16

Options Overview Details

View History
  • Implied Volatility 51.25% ( +1.18%)
  • Historical Volatility 35.07%
  • IV Percentile 20%
  • IV Rank 8.14%
  • IV High 443.77% on 08/05/24
  • IV Low 16.46% on 05/21/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 458
  • Volume Avg (30-Day) 834
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 38,822
  • Open Int (30-Day) 36,660

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.42 +2.34%
on 11/20/24
4.12 -15.05%
on 10/23/24
-0.57 (-14.00%)
since 10/21/24
3-Month
3.42 +2.34%
on 11/20/24
4.72 -25.93%
on 09/09/24
-0.37 (-9.56%)
since 08/21/24
52-Week
1.79 +95.53%
on 11/28/23
4.72 -25.93%
on 09/09/24
+1.67 (+91.26%)
since 11/21/23

Most Recent Stories

More News
Arbutus Biopharma Reports 50% Functional Cure Rate in Phase 2a Clinical Trial for Chronic Hepatitis B Virus

Arbutus Biopharma reports 50% functional cure rate in HBeAg-negative patients with low HBsAg after IM-PROVE I trial.Quiver AI SummaryArbutus Biopharma Corporation announced promising results from its IM-PROVE...

ABUS : 3.49 (+1.45%)
Arbutus Biopharma and Barinthus Bio Report Encouraging Preliminary Results from Phase 2a IM-PROVE II Clinical Trial for Chronic Hepatitis B Virus

Imdusiran, VTP-300, and low-dose nivolumab demonstrated significant HBsAg reduction in a Phase 2a clinical trial for chronic hepatitis B.Quiver AI SummaryArbutus Biopharma and Barinthus Biotherapeutics...

ABUS : 3.49 (+1.45%)
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

ABUS : 3.49 (+1.45%)
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

ABUS : 3.49 (+1.45%)
Arbutus to Present at Jefferies London Healthcare Conference

ABUS : 3.49 (+1.45%)
Arbutus: Q3 Earnings Snapshot

Arbutus: Q3 Earnings Snapshot

ABUS : 3.49 (+1.45%)
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ABUS : 3.49 (+1.45%)
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

ABUS : 3.49 (+1.45%)
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

ABUS : 3.49 (+1.45%)
Arbutus: Q2 Earnings Snapshot

Arbutus: Q2 Earnings Snapshot

ABUS : 3.49 (+1.45%)

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 3.63
2nd Resistance Point 3.59
1st Resistance Point 3.51
Last Price 3.49
1st Support Level 3.39
2nd Support Level 3.35
3rd Support Level 3.27

See More

52-Week High 4.72
Fibonacci 61.8% 3.60
Last Price 3.49
Fibonacci 50% 3.26
Fibonacci 38.2% 2.91
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar